Synthesis and evaluation of CD44 antibody-targeting cisplatin encapsulated PLGA submicron particles for therapy of ovarian cancer cell line

• Main Authors: Sheng-zhong Liu, 劉盛忠
• Other Authors: Meng-yi Bai
• Format: Others
• Language: zh-TW
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/67240266936107494246

碩士 === 國立臺灣科技大學 === 醫學工程研究所 === 101 === In this research, we used electrospray system synthesized poly(lactide-co-glycolide) acid cicplatin encapsulated submicron drug carriers, and conjugated with traditional bioconjugation method or directly mixed with maleimide-poly(ethylene glycol)-amine, in order to modify the surface of these drug carriers, for the application of further antibody conjugation. As a result, we found out that there are inefficiencies in the traditional bioconjugation method, which for example include dehydrogenation of maleimide to maleic acid, and ends up with unefficient antibody conjugating. In contrast, submicron particles prepared by electrospray containing blended maleimide showed efficient antibody conjugation, and active targeting property toward CD44 antigen, the average diameter of drug carriers prepared are 525±99 nm, and the conjugation rate is 12-15%. According to the In-vitro release profile, cisplatin encapsulated PEG/PLGA can reach 100% release in 72 hours because of hydrophilic mal-PEG-NH2 contained. Finally, we used CD44 over expressed ovarian cancer cell line, CP70 and SKOV3 to do the In-vitro cancer inhibition test. The results came to 10 % more efficient that free form of cisplatin solution, the possible mechanism is receptor-mediated endocytosis, which promises better transfection efficiency.